Iida Vähätalo

Iida Vähätalo

Auto-generated profile, based on publicly available information

Iida Vähätalo

Department of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
IVIida Vähätalo
Iida Vähätalo
PIPinja Ilmarinen
Pinja Ilmarinen
LTLeena E. Tuomisto
Leena E. Tuomisto
MTMinna Tommola
Minna Tommola
ONOnni Niemelä
Onni Niemelä
HKHannu Kankaanranta
Hannu Kankaanranta
Adherence to inhaled corticosteroids (ICS) has been suggested to be poor but long-term follow-ups are lacking. The objective of the present study was to assess adherence to ICS treatment in patients with adult-onset asthma during 12-year follow-up.A total of 181 patients with clinically confirmed, new-onset adult asthma were followed for 12 years as part of the Seinäjoki Adult Asthma Study. Adherence to ICS was assessed individually as the percentage of true dispensed ICS in micrograms per true prescribed daily ICS in micrograms over 12 years.Mean 12-year adherence to ICS was 69% (mean±sddispensed 2.5±1.8 g and prescribed 3.6±1.5 g budesonide equivalent per patient for 12 years), annual adherence varying between 81% (year 1) and 67% (year 12). Patients with good 12-year adherence (≥80%) used oral corticosteroids more often, and had add-on drugs in use and asthma-related visits to healthcare more often. In addition, they showed less reversibility in forced expiratory volume in 1 s and had higher peripheral blood neutrophil counts. However, lung function decline was steeper in patients with poorer adherence (<80%) and this association remained in multiple linear regression analysis. No difference was found in symptom scores, blood eosinophil counts, exhaled nitric oxide or immunoglobulin E between the patients with different levels of adherence.In patients with adult-onset asthma, adherence to ICS was moderate. Poorer adherence (<80%) to ICS was associated with more rapid decline in lung function but was not associated to symptoms or markers of inflammatory endotypes.

8 October 2020 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
PIPinja Ilmarinen
Pinja Ilmarinen
APAdrienn Pardo
Adrienn Pardo
LTLeena E. Tuomisto
Leena E. Tuomisto
IVIida Vähätalo
Iida Vähätalo
ONOnni Niemelä
Onni Niemelä
HKHannu Kankaanranta
Hannu Kankaanranta
Background: Obesity has been associated with poor outcomes of asthma in cross-sectional studies, but long-term effect of obesity on asthma remains unknown.Aims: To study the effects of obesity, found at the time of diagnosis of adult-onset asthma, on 12-year prognosis by focusing on oral corticosteroid (OCS) use and respiratory-related hospital admissions.Methods: Patients diagnosed with adult-onset asthma (n=203) were divided into three categories based on diagnostic body mass index (BMI) (<25 kg·m−2, 25–29.9 kg·m−2, ≥30 kg·m−2) and followed for 12 years as part of the Seinäjoki Adult Asthma Study. Self-reported and dispensed OCS were assessed for the 12-year period. Data on hospital admissions were analysed based on medical records.Results: 12 years after diagnosis, 86% of the patients who were obese (BMI ≥30 kg·m−2) at diagnosis remained obese. During the follow-up, no difference was found in weight gain between the BMI categories. During the 12-year follow-up, patients obese at diagnosis reported more frequent use of OCS courses (46.9%versus23.1%, p=0.028), were dispensed OCS more often (81.6%versus56.9%, p=0.014) and at higher doses (median 1350 (interquartile range 280–3180) mgversus600 (0–1650) mg prednisolone, p=0.010) compared to normal-weight patients. Furthermore, patients who were obese had more often one or more respiratory-related hospitalisations compared to normal-weight patients (38.8%versus16.9%, p=0.033). In multivariate logistic regression analyses, obesity predicted OCS use and hospital admissions.Conclusions: In adult-onset asthma, patients obese at diagnosis mostly remained obese at long-term and had more exacerbations and respiratory-related hospital admissions compared to normal-weight patients during 12-year follow-up. Weight loss should be a priority in their treatment to prevent this outcome.

1 April 2018 in Respiratory Medicine
Verified
Journal Article
Closed access
IVIida Vähätalo
Iida Vähätalo
PIPinja Ilmarinen
Pinja Ilmarinen
LTLeena E. Tuomisto
Leena E. Tuomisto
ONOnni Niemelä
Onni Niemelä
HKHannu Kankaanranta
Hannu Kankaanranta

14 January 2021 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
IVIida Vähätalo
Iida Vähätalo
HKHannu Kankaanranta
Hannu Kankaanranta
LTLeena E. Tuomisto
Leena E. Tuomisto
ONOnni Niemelä
Onni Niemelä
LLLauri Lehtimäki
Lauri Lehtimäki
PIPinja Ilmarinen
Pinja Ilmarinen
Background: In short-term studies, poor adherence to inhaled corticosteroids (ICS) has been associated with worse asthma control, but the association of long-term adherence and disease control remains unclear.Objective: To assess the relationship between 12-year adherence to ICS and asthma control in patients with adult-onset asthma.Methods: As part of the Seinäjoki Adult Asthma Study, 181 patients with clinically confirmed new-onset adult asthma and regular ICS medication were followed-up for 12 years. Adherence (%) to ICS was assessed individually ((µg dispensed/µg prescribed)×100) during the follow-up. Asthma control was evaluated after 12 years of treatment according to the Global Initiative for Asthma 2010 guideline.Results: Asthma was controlled in 31% and not controlled (partly controlled or uncontrolled) in 69% of the patients. Patients with not-controlled asthma were more often male, older, nonatopic and used higher doses of ICS than those with controlled disease. The mean±sd12-year adherence to ICS was 63±38% in patients with controlled asthma and 76±40% in patients with not-controlled disease (p=0.042). Among patients with not-controlled asthma, those with lower 12-year adherence (<80%) had more rapid decline in forced expiratory volume in 1 s (−47 mL·year−1) compared to patients with better adherence (≥80%) (−40 mL·year−1) (p=0.024). In contrast, this relationship was not seen in patients with controlled asthma.Conclusions: In adult-onset asthma, patients with not-controlled disease showed better 12-year adherence to ICS treatment than those with controlled asthma. In not-controlled disease, adherence <80% was associated with more rapid lung function decline, underscoring the importance of early recognition of such patients in routine clinical practice.

8 April 2022 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Open access
IVIida Vähätalo
Iida Vähätalo
LLLauri Lehtimäki
Lauri Lehtimäki
LTLeena E. Tuomisto
Leena E. Tuomisto
JKJussi Karjalainen
Jussi Karjalainen
ONOnni Niemelä
Onni Niemelä
HKHannu Kankaanranta
Hannu Kankaanranta
Short-term studies have associated high use of short-acting β2-agonists (SABA) with increased risk of exacerbations, emergency visits, and asthma-related costs. However, no studies exist on long-term SABA use, and previous studies on the topic have not included information about adherence to inhaled corticosteroids (ICS) nor disease control, both affecting the need of SABA. To evaluate the clinical characteristics of SABA and ICS usage in newly diagnosed adult-onset asthma patients during a 12-year follow-up period. In the Seinäjoki Adult Asthma Study, 203 patients with adult-onset asthma were followed for 12 years. Information on dispensed SABA and ICS during the follow-up was obtained from the Finnish Social Insurance Institution. High SABA use was defined as ≥36 canisters in 12 years, corresponding to an average of ≥3 dispensed canisters/y. Patients were dispensed median 6 (interquartile range: 3-16) SABA canisters and 48 (18-67) ICS canisters over 12 years, corresponding to 2 (1-4) and 11 (5-16) puffs/week, respectively. Only 10% of the patients were classified as high SABA users during this period. Obesity (body mass index ≥30) and high Airways Questionnaire 20 symptom scores at baseline predicted high long-term SABA use (incidence rate ratio: 1.53 [1.01-2.30] and 1.04 [1.00-1.08], respectively). High SABA users had higher ICS adherence, higher blood neutrophil counts, more comorbidities, and used more oral corticosteroid and antibiotic courses versus low SABA users. High SABA use was infrequent in patients with confirmed adult-onset asthma. However, as high SABA use is associated with more severe asthma, these patients should be recognized in clinical practice.

9 March 2024 in npj Primary Care Respiratory Medicine
Verified
Journal Article
Open access
PDF file
JTJaana Takala
Jaana Takala
IVIida Vähätalo
Iida Vähätalo
LTLeena E. Tuomisto
Leena E. Tuomisto
ONOnni Niemelä
Onni Niemelä
PIPinja Ilmarinen
Pinja Ilmarinen
HKHannu Kankaanranta
Hannu Kankaanranta
Systematically assessing asthma during follow-up contacts is important to accomplish comprehensive treatment. No previous long-term studies exist on how comorbidities, lifestyle factors, and asthma management details are documented in scheduled asthma contacts in primary health care (PHC). We showed comorbidities and lifestyle factors were poorly documented in PHC in this real-life, 12-year, follow-up study. Documented information on rhinitis was found in 8.9% and BMI, overweight, or obesity in ≤1.5% of the 542 scheduled asthma contacts. Of the 145 patients with scheduled asthma contacts, 6.9% had undergone revision of their inhalation technique; 16.6% had documentation of their asthma action plan. Screening of respiratory symptoms was recorded in 79% but nasal symptoms in only 15.5% of contacts. Lifestyle guidance interventions were found in <1% of contacts. These results, based on documented patient data, indicate a need exists to further improve the assessment and guidance of asthma patients in PHC.